Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Deep dives into peptide science — evidence-graded, honestly reported
The same TRT protocol becomes a fundamentally different risk proposition at 30 than at 50. Here's where the calculus shifts, and where peptides start winning specific trades.
After 35, cardiovascular remodeling accelerates, prostate risk compounds, and HPTA recovery narrows. This article maps the age-stratified risk data for TRT and identifies where GH secretagogues, the Wolverine Stack, and Sermorelin offer lower-cost alternatives for specific outcomes.
Comprehensive outcome research with safety data and practical protocol references
How a fragment of growth hormone is rewriting the rules of targeted fat loss — and why the FDA just pulled the plug.
AOD 9604 isolates the fat-burning signal of growth hormone while leaving the growth-promoting pathways untouched. Five surprising truths about the peptide the FDA reclassified overnight.
Detailed compound profiles with mechanisms, safety data, and dosing protocols
A synthetic GHRH analog that tells your pituitary to release its own growth hormone, not inject someone else's.
CJC-1295 is a 29-amino acid GHRH analog engineered to resist enzymatic breakdown. It stimulates endogenous GH pulses rather than flooding the system with synthetic hormone, offering a fundamentally different risk-benefit profile to direct HGH therapy.
Evidence-based supplement stacks designed to support your peptide protocols
The biochemical cofactors your body needs to support CJC-1295 therapy.
Evidence-based supplement companion for CJC-1295 , a synthetic GHRH analog that tells your pituitary to release its own growth hormone, not inject someone else's.
35+
Articles
18
Categories